Incidence of Kidney Disease

Benzinga  7 hrs ago  Comment 
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced the successful completion of...
Benzinga  Sep 28  Comment 
Akebia Therapeutics Inc (NASDAQ: AKBA) is developing a safer treatment for anemia in patients with Chronic Kidney Disease. The compound, AKB-6548, is expected to go into Phase III clinical trials soon. AKB-6548 is an oral therapy designed to be...
NPR  Sep 27  Comment 
There comes a time when a drug that once helped a patient may be unnecessary or even harmful. Figuring out when to cut back is difficult, but the potential benefits are substantial.
Benzinga  Sep 24  Comment 
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the European Commission has approved Fexeric® (ferric citrate coordination complex) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with...
New York Times  Sep 14  Comment 
The condition is so common in older patients that some experts wonder whether it should be considered a disease.
FierceBiotech  Sep 1  Comment 
Sanofi is backing out of a collaboration with Ardelyx that could have paid out nearly $200 million, returning a handful of candidate treatments for high phosphates in patients with kidney disease.  Aug 25  Comment 
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) said it has submitted a New Drug Application or NDA with the United States Food and Drug Administration or FDA for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism or SHPT...
MedPage Today  Jul 30  Comment 
(MedPage Today) -- Feasibility of mobile technology in CKD tested
MedPage Today  Jul 30  Comment 
(MedPage Today) -- Atrius Health improves chronic kidney disease care through enhanced Medicare data

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki